BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.
Science. 2011 Oct 28; 334(6055):525-8
Shakya R, Reid LJ, Reczek CR, Cole F, ..., Szabolcs M, Jasin M, Baer R, Ludwig T. Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS, deRooij DG, Hirsch S, Ravi K, Hicks JB, Szabolcs M, Jasin M, Baer R, Ludwig T. Science. 2011 Oct 28; 334(6055):525-8
"One Ring to Rule Them All" - in the case of breast cancer 1 (BRCA1), maybe not. The breast and ovarian tumor suppressor BRCA1 contains a C-terminal pair of BRCT domains that bind to phosphoproteins, and a RING finger domain that, in combination with BARD1, functions as an E3 ubiquitin ligase. The relative importance of these do and...
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.